Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients
Background: Methotrexate (MTX), a traditional antipsoriatic drug, is very frequently used either as monotherapy or in combination with other systemic drugs. Objectives: To assess the effectiveness and safety of MTX in psoriasis in usual clinical practice. Methods: We conducted a retrospective study....
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2016.1273469 |
| _version_ | 1797683994040467456 |
|---|---|
| author | Camila Cabello Zurita Mercè Grau Pérez Carlos Pelayo Hernández Fernández Alicia González Quesada Pedro Valerón Almazán Jaime Vilar Alejo Gregorio Carretero Hernández |
| author_facet | Camila Cabello Zurita Mercè Grau Pérez Carlos Pelayo Hernández Fernández Alicia González Quesada Pedro Valerón Almazán Jaime Vilar Alejo Gregorio Carretero Hernández |
| author_sort | Camila Cabello Zurita |
| collection | DOAJ |
| description | Background: Methotrexate (MTX), a traditional antipsoriatic drug, is very frequently used either as monotherapy or in combination with other systemic drugs. Objectives: To assess the effectiveness and safety of MTX in psoriasis in usual clinical practice. Methods: We conducted a retrospective study. We performed an electronic and manual chart review of patients treated with MTX in the Psoriasis Unit of our Hospital from January 2007 to December 2014. Demographic and clinical data, PASI/DLQI scores and reasons for suspension of all patients treated with MTX in usual clinical practice were recorded. Results: Two hundred and eighteen patients were included. MTX was administered in 67% of cases as the first systemic treatment. The average treatment duration was 17.2 ± 13.6 months. All patients were subjected to clinical and laboratory monitoring. About 33.5% of them achieved a reduction of 75% or more of the initial PASI at week 12, 34.9% at week16, 44.7% at week 24, and 52.8% at week 48. A 3.3% had to discontinue the therapy due to analytical hepatic (2.8%) or renal (0.5%) abnormalities. Only one patient experienced severe interstitial pneumonitis and none required liver biopsy. Conclusions: MTX is an effective and safe option for the treatment of psoriasis in the real-world clinical practice. |
| first_indexed | 2024-03-12T00:22:57Z |
| format | Article |
| id | doaj.art-457f6c5068ac464ca2abdd1c7ff94ba3 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:22:57Z |
| publishDate | 2017-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-457f6c5068ac464ca2abdd1c7ff94ba32023-09-15T10:48:03ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532017-07-0128540140510.1080/09546634.2016.12734691273469Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patientsCamila Cabello Zurita0Mercè Grau Pérez1Carlos Pelayo Hernández Fernández2Alicia González Quesada3Pedro Valerón Almazán4Jaime Vilar Alejo5Gregorio Carretero Hernández6Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaHospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran CanariaBackground: Methotrexate (MTX), a traditional antipsoriatic drug, is very frequently used either as monotherapy or in combination with other systemic drugs. Objectives: To assess the effectiveness and safety of MTX in psoriasis in usual clinical practice. Methods: We conducted a retrospective study. We performed an electronic and manual chart review of patients treated with MTX in the Psoriasis Unit of our Hospital from January 2007 to December 2014. Demographic and clinical data, PASI/DLQI scores and reasons for suspension of all patients treated with MTX in usual clinical practice were recorded. Results: Two hundred and eighteen patients were included. MTX was administered in 67% of cases as the first systemic treatment. The average treatment duration was 17.2 ± 13.6 months. All patients were subjected to clinical and laboratory monitoring. About 33.5% of them achieved a reduction of 75% or more of the initial PASI at week 12, 34.9% at week16, 44.7% at week 24, and 52.8% at week 48. A 3.3% had to discontinue the therapy due to analytical hepatic (2.8%) or renal (0.5%) abnormalities. Only one patient experienced severe interstitial pneumonitis and none required liver biopsy. Conclusions: MTX is an effective and safe option for the treatment of psoriasis in the real-world clinical practice.http://dx.doi.org/10.1080/09546634.2016.1273469methotrexatepsoriasiseffectivenesssafetyreal-world clinical practice |
| spellingShingle | Camila Cabello Zurita Mercè Grau Pérez Carlos Pelayo Hernández Fernández Alicia González Quesada Pedro Valerón Almazán Jaime Vilar Alejo Gregorio Carretero Hernández Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients Journal of Dermatological Treatment methotrexate psoriasis effectiveness safety real-world clinical practice |
| title | Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients |
| title_full | Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients |
| title_fullStr | Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients |
| title_full_unstemmed | Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients |
| title_short | Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients |
| title_sort | effectiveness and safety of methotrexate in psoriasis an eight year experience with 218 patients |
| topic | methotrexate psoriasis effectiveness safety real-world clinical practice |
| url | http://dx.doi.org/10.1080/09546634.2016.1273469 |
| work_keys_str_mv | AT camilacabellozurita effectivenessandsafetyofmethotrexateinpsoriasisaneightyearexperiencewith218patients AT mercegrauperez effectivenessandsafetyofmethotrexateinpsoriasisaneightyearexperiencewith218patients AT carlospelayohernandezfernandez effectivenessandsafetyofmethotrexateinpsoriasisaneightyearexperiencewith218patients AT aliciagonzalezquesada effectivenessandsafetyofmethotrexateinpsoriasisaneightyearexperiencewith218patients AT pedrovaleronalmazan effectivenessandsafetyofmethotrexateinpsoriasisaneightyearexperiencewith218patients AT jaimevilaralejo effectivenessandsafetyofmethotrexateinpsoriasisaneightyearexperiencewith218patients AT gregoriocarreterohernandez effectivenessandsafetyofmethotrexateinpsoriasisaneightyearexperiencewith218patients |